CATX - Perspective Therapeutics, Inc.

QQQ $ 608.57 $ 0.46 (0.08 %)

DIA $ 471.86 $ -2.94 (-0.62 %)

SPY $ 671.75 $ -0.11 (-0.02 %)

TLT $ 88.93 $ -0.51 (-0.57 %)

GLD $ 375.85 $ -6.91 (-1.8 %)

Previous Close

$ 2.07

Open

$ 2.09

Bid

$ 2.09 x 1,357

Ask

$ 2.09 x 961

Day's Range

$ 2.05 - $ 2.22

52 Week Range

$ 1.60 - $ 10.06

Volume

4,987,609

Average Volume

Market Cap

153.88M

Beta (5Y Monthly)

$ 1.14

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-10-2025	09-30-2025	10-Q
2	08-13-2025	06-30-2025	10-Q
3	05-12-2025	03-31-2025	10-Q
4	03-26-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-13-2024	06-30-2024	10-Q
7	05-15-2024	03-31-2024	10-Q
8	03-28-2024	12-31-2023	10-K
9	11-14-2023	09-30-2023	10-Q
10	08-11-2023	06-30-2023	10-Q
11	05-15-2023	03-31-2023	10-Q
12	11-14-2022	09-30-2022	10-Q
13	09-28-2022	06-30-2022	10-K
14	05-12-2022	03-31-2022	10-Q
15	02-09-2022	12-31-2021	10-Q
16	11-10-2021	09-30-2021	10-Q
17	09-27-2021	06-30-2021	10-K
18	05-14-2021	03-31-2021	10-Q
19	02-09-2021	12-31-2020	10-Q
20	11-13-2020	09-30-2020	10-Q
21	09-25-2020	06-30-2020	10-K
22	05-13-2020	03-31-2020	10-Q
23	02-12-2020	12-31-2019	10-Q
24	11-13-2019	09-30-2019	10-Q
25	09-27-2019	06-30-2019	10-K
26	05-10-2019	03-31-2019	10-Q
27	02-13-2019	12-31-2018	10-Q
28	11-09-2018	09-30-2018	10-Q
29	09-26-2018	06-30-2018	10-K
30	05-04-2018	03-31-2018	10-Q
31	02-09-2018	12-31-2017	10-Q
32	11-14-2017	09-30-2017	10-Q
33	09-28-2017	06-30-2017	10-K
34	05-10-2017	03-31-2017	10-Q
35	02-09-2017	12-31-2016	10-Q
36	11-09-2016	09-30-2016	10-Q
37	09-09-2016	06-30-2016	10-K
38	05-10-2016	03-31-2016	10-Q
39	02-09-2016	12-31-2015	10-Q
40	11-09-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Perspective Therapeutics Q3 EPS $(0.35) Mi...
11/10/2025 21:06:10

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate...

Earnings Scheduled For November 10, 2025
11/10/2025 11:12:02

12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

Perspective Therapeutics Reports 44% Confi...
10/20/2025 08:34:30

Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-t...

BTIG Reiterates Buy on Perspective Therape...
10/13/2025 13:57:29

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.

12 Health Care Stocks Moving In Friday's I...
10/10/2025 17:06:47

this-aptiv-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday

This Aptiv Analyst Begins Coverage On A Bu...
10/10/2025 13:25:06

BTIG Initiates Coverage On Perspective The...
10/10/2025 10:26:24

BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Pric...

HC Wainwright & Co. Reiterates Buy on Pers...
10/03/2025 11:33:35

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

Perspective Therapeutics Announces First P...
10/02/2025 11:03:40

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that...

HC Wainwright & Co. Reiterates Buy on Pers...
09/19/2025 11:32:47

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

Perspective Therapeutics Says First Patien...
09/15/2025 11:08:23

First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-ope...

Perspective Therapeutics Names Joel Sendek...
09/04/2025 11:24:45

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

Perspective Therapeutics Q2 EPS $(0.30), I...
08/13/2025 10:47:56

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. T...

Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

A Look Ahead: Perspective Therapeutics's E...
08/12/2025 20:02:48

Perspective Therapeutics To Present Update...
07/24/2025 16:46:42

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

B. Riley Securities Maintains Buy on Persp...
06/23/2025 18:05:32

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target f...

Wedbush Reiterates Outperform on Perspecti...
06/23/2025 13:40:12

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price...

Reported Saturday, Perspective Therapeutic...
06/23/2025 08:18:21

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) th...